Evidence map›Paper›PMID 33821622›Full record

ArticleBiomacromolecules2021

Understanding the Formation of Apoferritin Amyloid Fibrils.

Rocío Jurado, Jozef Adamcik, Antoni Sánchez-Ferrer, Sreenath Bolisetty, Raffaele Mezzenga, Natividad Gálvez

Open access · hybridAbstract read
In one paragraph

Article in Biomacromolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Rocío JuradoDepartment of Inorganic Chemistry, University of Granada, 18071 Granada, Spain.
Jozef AdamcikDepartment of Health Sciences and Technology, ETH Zürich, 8092 Zürich, Switzerland.
Antoni Sánchez-FerrerDepartment of Health Sciences and Technology, ETH Zürich, 8092 Zürich, Switzerland.
Sreenath BolisettyDepartment of Health Sciences and Technology, ETH Zürich, 8092 Zürich, Switzerland.
Raffaele MezzengaDepartment of Health Sciences and Technology, ETH Zürich, 8092 Zürich, Switzerland.ORCID 0000-0002-5739-2610
Natividad GálvezDepartment of Inorganic Chemistry, University of Granada, 18071 Granada, Spain.ORCID 0000-0003-4286-6278
ETH Zurich · CHUniversidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the optimization of experimental conditions to yield long, rigid apoferritin protein amyloid fibrils, as well as the corresponding fibrillation pathway. Fibril growth kinetics was followed using atomic force microscopy (AFM), transmission electron microscopy (TEM), dynamic light scattering (DLS), circular dichroism (CD), fourier-transform infrared spectroscopy (FTIR), and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Among the morphologies identified, we show that the conditions result in small aggregates, as well as medium and long fibrils. Extended incubation times led to progressive unfolding and hydrolysis of the proteins into very short peptide fragments. AFM, SDS-PAGE, and CD support a universal common fibrillation mechanism in which hydrolyzed fragments play the central role. These collective results provide convincing evidence that protein unfolding and complete hydrolysis of the proteins into very short peptide sequences are essential for the formation of the final apoferritin amyloid-like fibrils.

Indexed as

AmyloidApoferritinsAmyloid beta-PeptidesCircular DichroismElectrophoresis, Polyacrylamide GelMicroscopy, Atomic ForceSpectroscopy, Fourier Transform InfraredAmyloidAmyloid beta-PeptidesApoferritins

Identifiers

PMID33821622
PMCPMC8462754
OpenAlexW3140644376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.